Live Analyst Rating Changes 9251 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Joseph Thome
TD
Joseph Thome
TD Cowen
Wall Street Analyst
★★★☆☆
#1344
on 13Foresight · ranked by our own returns
56%
Success Rate
+6.2%
Average Return
22 of 39 calls profitable · +1.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 56% of Joseph Thome's ratings turned a profit when each position was held for 1 year — averaging +6.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

148 Buy 9 Hold 0 Sell
Joseph's Stock Coverage 29 ratings · 2026-07-17
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
RAPP
Rapport Therapeutics, Inc.
 Jul 17, 2026 BUY Strong Buy
+36.1% avg upside
13 analysts
 — ·
ANAB
AnaptysBio
 Jul 13, 2026 BUY Strong Buy
+32.9% avg upside
26 analysts
$75.00
38.50% Upside
 ·
ALKS
Alkermes
 Jul 13, 2026 BUY Strong Buy
-23.2% avg upside
34 analysts
$57.00
9.77% Upside
 -0.5%
ARWR
Arrowhead Pharmaceuticals
 Jun 30, 2026 BUY Strong Buy
-4.7% avg upside
27 analysts
 — -11.9%
DYN
Dyne Therapeutics
 Jun 26, 2026 BUY Strong Buy
+64.0% avg upside
30 analysts
 — +13.6%
QURE
uniQure
 Jun 17, 2026 BUY Strong Buy
+48.3% avg upside
29 analysts
 — -18.3%
AXSM
Axsome Therapeutics
 Jun 16, 2026 BUY Strong Buy
-6.4% avg upside
28 analysts
$300.00
26.65% Upside
 +0.1%
NTLA
Intellia Therapeutics
 Jun 14, 2026 BUY Buy
+215.8% avg upside
37 analysts
 — -4.7%
JAZZ
Jazz Pharmaceuticals
 Jun 12, 2026 BUY Strong Buy
-7.5% avg upside
35 analysts
$275.00
13.62% Upside
 +5.1%
NGEN
NervGen Pharma
 Jun 11, 2026 BUY Strong Buy
+477.6% avg upside
9 analysts
 — -11.6%
UTHR
United Therapeutics
 Jun 05, 2026 BUY Strong Buy
-20.2% avg upside
26 analysts
$675.00
27.51% Upside
 -3.7%
DRUG
Bright Minds Biosciences
 May 20, 2026 BUY Strong Buy
+79.6% avg upside
10 analysts
 — -10.3%
MPLT
MapLight Therapeutics, Inc.
 May 14, 2026 BUY Strong Buy
+7.0% avg upside
12 analysts
 — +29.4%
MGX
Metagenomi, Inc.
 May 11, 2026 BUY Strong Buy
+608.4% avg upside
8 analysts
 — -2.2%
DNLI
Denali Therapeutics
 May 08, 2026 BUY Strong Buy
+65.9% avg upside
24 analysts
 — +30.9%
PTCT
PTC Therapeutics
 May 08, 2026 BUY Buy
+0.5% avg upside
29 analysts
$90.00
14.64% Upside
 +7.0%
MIRM
Mirum Pharmaceuticals
 May 07, 2026 BUY Strong Buy
-0.5% avg upside
21 analysts
$145.00
23.47% Upside
 +17.6%
PRME
Prime Medicine, Inc.
 May 07, 2026 BUY Strong Buy
+194.9% avg upside
16 analysts
 — +9.6%
TRDA
Entrada Therapeutics Inc
 May 07, 2026 BUY Strong Buy
+205.2% avg upside
10 analysts
 — -3.6%
XENE
Xenon
 May 07, 2026 BUY Strong Buy
-5.9% avg upside
28 analysts
 — +20.9%
VRDN
Viridian Therapeutics
 May 05, 2026 BUY Strong Buy
+93.1% avg upside
32 analysts
 — +5.3%
AMLX
Amylyx Pharmaceuticals Inc
 May 05, 2026 BUY Strong Buy
+43.1% avg upside
14 analysts
 — +3.6%
ARDX
Ardelyx
 Apr 30, 2026 BUY Strong Buy
+172.4% avg upside
21 analysts
$13.00
153.67% Upside
 -18.8%
MCRB
Seres Therapeutics
 Nov 05, 2025 BUY Buy
+218.3% avg upside
11 analysts
 — -59.2%
JBIO
Jade Biosciences
 Jul 19, 2024 HOLD Strong Buy
+173.4% avg upside
16 analysts
 — -84.4%
EVLO
Evelo Biosciences
 Oct 17, 2023 HOLD Buy
+44999900.0% avg upside
5 analysts
 — ·
PTC
PTC
 May 24, 2023 HOLD Strong Buy
+18.8% avg upside
31 analysts
$40.00
68.60% Downside
 +40.4%
HLIT
Harmonic
 Oct 10, 2022 BUY Buy
+5.1% avg upside
14 analysts
 — -30.5%
PVLA
Palvella Therapeutics
 Oct 01, 2020 BUY Strong Buy
+12.1% avg upside
27 analysts
 — +151.7%
🔒 24 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Joseph Thome — Frequently Asked Questions
How accurate are Joseph Thome's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Joseph's ratings were profitable over a one-year hold, with an average return of +6.2% per rating, or +1.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Joseph ranked on 13Foresight?
Joseph Thome is currently ranked #1344 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Joseph cover?
Joseph most recently has ratings on RAPP, ANAB, ALKS, ARWR, DYN, QURE, AXSM, NTLA, JAZZ, NGEN, UTHR, DRUG and 17 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.